FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2084778105> ?p ?o ?g. }

• W2084778105 abstract "The effects of sorafenib in the treatment of advanced renal cell carcinoma (RCC) have been confirmed in an international collaborative phase III trial. This study aims to confirm similar efficacy and treatment-induced toxicities of sorafenib in the treatment of metastatic RCC in ethnic Chinese patients.Ninety-eight consecutive and non-selected patients with pathologically confirmed metastatic RCC were treated according to an institutional treatment protocol. All patients were treated with 400 mg of sorafenib orally twice daily on a continuous basis until disease progression or intolerance to treatment occurred. Dose reduction to 400 mg once daily was required if grade 3 or 4 toxicities occurred. All patients except for 7 received nephrectomy in the course of their disease. All patients were assessed for tumor response, progression-free survival (PFS), overall survival (OS), and treatment-induced toxicities.The median follow-up time was 76 weeks (range 2-296 weeks) for the entire group of patients. Radiologically confirmed complete response (CR), partial response (PR), stable disease (SD) of more than 4 months, and disease progression as best objective responses were observed in 1 (1%), 23 (23.5%), 62 (63.3%), and 12 (12.2%) patients, respectively. The tumor control rate (CR+PR+SD of >4 months) was 87.8%. The 1-year estimated PFS and OS were 58.4% and 64.6%, respectively. The median progression-free survival (PFS) time was 60 weeks (95% CI 41-79); and the median overall survival (OS) time was not reached with a follow-up of 76 weeks. Reduction of sorafenib dose was required in 26 patients who developed grade 3 or 4 treatment-cause adverse-effects. An additional 9 patients discontinued sorafenib treatment due to severe adverse-effects. No grade 5 toxicity occurred.Multivariate analysis revealed that independent predictive factors for tumor response to sorafenib treatment included ECOG status, presence of lymph node metastasis, and nephrectomy prior to the development of metastasis.Sorafenib produced an 87.8% disease control rate for metastatic renal cell carcinoma in Chinese patients, with acceptable rates of toxicity. The medication dosed at 400 mg twice daily is both efficacious and safe in the treatment of metastatic renal cell carcinoma in Chinese patients." @default.
• W2084778105 created "2016-06-24" @default.
• W2084778105 creator A5005403850 @default.
• W2084778105 creator A5009027431 @default.
• W2084778105 creator A5016243869 @default.
• W2084778105 creator A5023666246 @default.
• W2084778105 creator A5046427876 @default.
• W2084778105 creator A5053347862 @default.
• W2084778105 creator A5059183788 @default.
• W2084778105 creator A5061455453 @default.
• W2084778105 creator A5063059217 @default.
• W2084778105 creator A5082117229 @default.
• W2084778105 date "2009-07-21" @default.
• W2084778105 modified "2023-10-16" @default.
• W2084778105 title "Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study" @default.
• W2084778105 cites W1967232244 @default.
• W2084778105 cites W1971010709 @default.
• W2084778105 cites W1971837077 @default.
• W2084778105 cites W1982311138 @default.
• W2084778105 cites W1991551598 @default.
• W2084778105 cites W1994193851 @default.
• W2084778105 cites W1996283150 @default.
• W2084778105 cites W1999966467 @default.
• W2084778105 cites W2014330130 @default.
• W2084778105 cites W2021256410 @default.
• W2084778105 cites W2043696829 @default.
• W2084778105 cites W2052368352 @default.
• W2084778105 cites W2082331198 @default.
• W2084778105 cites W2085925464 @default.
• W2084778105 cites W2097415899 @default.
• W2084778105 cites W2115690668 @default.
• W2084778105 cites W2119930263 @default.
• W2084778105 cites W2138822094 @default.
• W2084778105 cites W2140765540 @default.
• W2084778105 cites W2149026055 @default.
• W2084778105 cites W2153477391 @default.
• W2084778105 cites W2162407658 @default.
• W2084778105 cites W2163844751 @default.
• W2084778105 cites W2167290534 @default.
• W2084778105 cites W2270408419 @default.
• W2084778105 cites W2768600953 @default.
• W2084778105 cites W4239180165 @default.
• W2084778105 cites W4293241248 @default.
• W2084778105 doi "https://doi.org/10.1186/1471-2407-9-249" @default.
• W2084778105 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2724546" @default.
• W2084778105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19622166" @default.
• W2084778105 hasPublicationYear "2009" @default.
• W2084778105 type Work @default.
• W2084778105 sameAs 2084778105 @default.
• W2084778105 citedByCount "47" @default.
• W2084778105 countsByYear W20847781052012 @default.
• W2084778105 countsByYear W20847781052013 @default.
• W2084778105 countsByYear W20847781052014 @default.
• W2084778105 countsByYear W20847781052015 @default.
• W2084778105 countsByYear W20847781052016 @default.
• W2084778105 countsByYear W20847781052017 @default.
• W2084778105 countsByYear W20847781052018 @default.
• W2084778105 countsByYear W20847781052019 @default.
• W2084778105 countsByYear W20847781052020 @default.
• W2084778105 countsByYear W20847781052021 @default.
• W2084778105 crossrefType "journal-article" @default.
• W2084778105 hasAuthorship W2084778105A5005403850 @default.
• W2084778105 hasAuthorship W2084778105A5009027431 @default.
• W2084778105 hasAuthorship W2084778105A5016243869 @default.
• W2084778105 hasAuthorship W2084778105A5023666246 @default.
• W2084778105 hasAuthorship W2084778105A5046427876 @default.
• W2084778105 hasAuthorship W2084778105A5053347862 @default.
• W2084778105 hasAuthorship W2084778105A5059183788 @default.
• W2084778105 hasAuthorship W2084778105A5061455453 @default.
• W2084778105 hasAuthorship W2084778105A5063059217 @default.
• W2084778105 hasAuthorship W2084778105A5082117229 @default.
• W2084778105 hasBestOaLocation W20847781051 @default.
• W2084778105 hasConcept C126322002 @default.
• W2084778105 hasConcept C126894567 @default.
• W2084778105 hasConcept C141071460 @default.
• W2084778105 hasConcept C143998085 @default.
• W2084778105 hasConcept C2776694085 @default.
• W2084778105 hasConcept C2777472916 @default.
• W2084778105 hasConcept C2778019345 @default.
• W2084778105 hasConcept C2778695046 @default.
• W2084778105 hasConcept C2779984678 @default.
• W2084778105 hasConcept C2780091579 @default.
• W2084778105 hasConcept C2780140570 @default.
• W2084778105 hasConcept C2780227381 @default.
• W2084778105 hasConcept C2780739268 @default.
• W2084778105 hasConcept C31760486 @default.
• W2084778105 hasConcept C535046627 @default.
• W2084778105 hasConcept C71924100 @default.
• W2084778105 hasConcept C90924648 @default.
• W2084778105 hasConceptScore W2084778105C126322002 @default.
• W2084778105 hasConceptScore W2084778105C126894567 @default.
• W2084778105 hasConceptScore W2084778105C141071460 @default.
• W2084778105 hasConceptScore W2084778105C143998085 @default.
• W2084778105 hasConceptScore W2084778105C2776694085 @default.
• W2084778105 hasConceptScore W2084778105C2777472916 @default.
• W2084778105 hasConceptScore W2084778105C2778019345 @default.
• W2084778105 hasConceptScore W2084778105C2778695046 @default.
• W2084778105 hasConceptScore W2084778105C2779984678 @default.
• W2084778105 hasConceptScore W2084778105C2780091579 @default.
• W2084778105 hasConceptScore W2084778105C2780140570 @default.

• next